Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kristoff Muylle

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Current Opinion in Oncology|April 9, 2005
18F-fluoro-2-deoxy-D-glucose positron emission tomographic imaging: recent developments in head and neck cancerKristoff Muylle, Catherine Castaigne, Patrick Flamen
Clinical Nuclear Medicine|October 31, 2019
68Ga-Prostate-Specific Membrane Antigen-11 PET/CT: A New Imaging Option for Recurrent Glioblastoma Multiforme?Jolanta Kunikowska, Radosław Kuliński, Kristoff Muylle, et al.
Clinical Cases in Mineral and Bone Metabolism : the Official Journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases|July 26, 2017
Primary hyperparathyroidism associated to thrombocytopenia: an issue to consider?Steven De Keukeleire, Kristoff Muylle, Georgios Tsoumalis, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 9, 2026
Eryhtropoetin induced <sup>18</sup>F-PSMA-11 bone marrow sink effectJustine Maes, Alex Maes, Kristoff Muylle, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 12, 2018
Correction to: Dosimetry in clinical radionuclide therapy: the devil is in the detailFrancesco Giammarile, Kristoff Muylle, Roberto Delgado Bolton, et al.
European Journal of Haematology|May 3, 2018
Long-term follow-up of 2 patients treated with <sup>90</sup> Y-rituximab radioimmunotherapy for relapse of nodular lymphocyte-predominant Hodgkin lymphomaSophie C Golstein, Kristoff Muylle, Marie Vercruyssen, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 17, 2019
Differentiated thyroid cancer patients potentially benefitting from postoperative I-131 therapy: a review of the literature of the past decadeFrederik A Verburg, Glenn Flux, Luca Giovanella, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 25, 2003
Optimal dose of 18F-FDG required for whole-body PET using an LSO PET cameraHendrik Everaert, Christian Vanhove, Tony Lahoutte, et al.
Cardiovascular and Interventional Radiology|September 26, 2012
Radioembolization of the spleen: a revisited approach for the treatment of malignant lymphomatous splenomegalyKristoff Muylle, Jasmine Nguyen, Alexandre de Wind, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 21, 2015
Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximabKristoff Muylle, Patrick Flamen, Danielle J Vugts, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Current Opinion in Oncology|April 9, 2005
18F-fluoro-2-deoxy-D-glucose positron emission tomographic imaging: recent developments in head and neck cancerKristoff Muylle, Catherine Castaigne, Patrick Flamen
Clinical Nuclear Medicine|October 31, 2019
68Ga-Prostate-Specific Membrane Antigen-11 PET/CT: A New Imaging Option for Recurrent Glioblastoma Multiforme?Jolanta Kunikowska, Radosław Kuliński, Kristoff Muylle, et al.
Clinical Cases in Mineral and Bone Metabolism : the Official Journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases|July 26, 2017
Primary hyperparathyroidism associated to thrombocytopenia: an issue to consider?Steven De Keukeleire, Kristoff Muylle, Georgios Tsoumalis, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 9, 2026
Eryhtropoetin induced <sup>18</sup>F-PSMA-11 bone marrow sink effectJustine Maes, Alex Maes, Kristoff Muylle, et al.
European Journal of Nuclear Medicine and Molecular Imaging|January 12, 2018
Correction to: Dosimetry in clinical radionuclide therapy: the devil is in the detailFrancesco Giammarile, Kristoff Muylle, Roberto Delgado Bolton, et al.
European Journal of Haematology|May 3, 2018
Long-term follow-up of 2 patients treated with <sup>90</sup> Y-rituximab radioimmunotherapy for relapse of nodular lymphocyte-predominant Hodgkin lymphomaSophie C Golstein, Kristoff Muylle, Marie Vercruyssen, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 17, 2019
Differentiated thyroid cancer patients potentially benefitting from postoperative I-131 therapy: a review of the literature of the past decadeFrederik A Verburg, Glenn Flux, Luca Giovanella, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 25, 2003
Optimal dose of 18F-FDG required for whole-body PET using an LSO PET cameraHendrik Everaert, Christian Vanhove, Tony Lahoutte, et al.
Cardiovascular and Interventional Radiology|September 26, 2012
Radioembolization of the spleen: a revisited approach for the treatment of malignant lymphomatous splenomegalyKristoff Muylle, Jasmine Nguyen, Alexandre de Wind, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 21, 2015
Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximabKristoff Muylle, Patrick Flamen, Danielle J Vugts, et al.
Pageof 2